Immune checkpoint inhibitors for advanced pancreatic cancer

Wei Yen Chan, Hao Wen Sim, Muhammad Abdi Haryono, Desmond Yip, Venessa Chin*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To evaluate the benefits and harms of immune checkpoint inhibitors (ICIs), as monotherapy or in combination (with chemotherapy or targeted therapy), for people with advanced pancreatic cancer compared with chemotherapy, targeted therapy, or placebo.

Original languageEnglish
Article numberCD014523
JournalCochrane Database of Systematic Reviews
Volume2023
Issue number2
DOIs
Publication statusPublished - 24 Feb 2023
Externally publishedYes

Fingerprint

Dive into the research topics of 'Immune checkpoint inhibitors for advanced pancreatic cancer'. Together they form a unique fingerprint.

Cite this